Abha Kundi’s Insights

40 total results. Page 1 of 4.

Alerts
Customs Cleared, Charges Pending: Counterfeit Ozempic Indictment Makes the Drug Supply Chain Security Act (DSCSA) an Import Compliance Issue
Alerts
No Immunity: Why Wellness and Longevity Brands Can Get Sued Before the FDA Ever Calls
Alerts
Tele-Vision: How Recent FDA and SEC Actions Forecast a Sharper Focus on Telehealth Prescribing Models
Alerts
How a Warning Letter Became a Wellness Playbook
Alerts
RUO-ined: Five Peptide Vendors Learn That ‘Research Use Only’ Is Not a Legal Strategy
Press Release
AFS Welcomes 2026 Fellows Class, Building on a Decade of Leadership Development
News
Kundi Featured on FDA Committee Peptide Vote
Alerts
A Refill on Relief: FDA Extends DSCSA Exemption for Small Dispensers as Assessment Begins
News
Kundi Quoted on FDA Committee Approval of Peptide Compounds
Alerts
The (Pep)Tides Turn: FDA Panel Recommends Six of Seven for Compounding
Alerts
Reinventing the Wheel: FDA’s Hub-and-Spoke Fix for Drug Manufacturing Registration
Alerts
50 Shades of Legally Gray: FDA’s Juicy Peptide Cliffhanger